Vitamin D and early rheumatoid arthritis.
Inflammation
Psoriatic arthritis
Rheumatoid arthritis
Undifferentiated inflammatory arthritis
Vitamin D
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
12
2019
accepted:
21
04
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
31
7
2020
Statut:
epublish
Résumé
Previous studies have linked rheumatoid arthritis (RA) risk and disease activity with vitamin D-deficiency (low serum 25-hydroxyvitamin D (25OHD)), but a causal role for vitamin D in RA is still unclear, with conflicting results from many previous studies, partly due to heterogeneity in study design and patient populations. In this study we aimed to (1) analyse serum 25OHD in early inflammatory arthritis, (2) compare 25OHD with disease activity and fatigue in early RA and (3) determine whether low 25OHD is associated with progression to RA. An analysis of 790 patients recruited to the Birmingham Early Inflammatory Arthritis Cohort and followed longitudinally to determine clinical outcomes. The following were recorded at baseline: demographic data, duration of symptoms, duration of early morning stiffness (EMS), tender and swollen joint counts, Visual Analogue Scale (VAS) pain/fatigue/EMS, PHQ-9, HAQ and FACIT-Fatigue scores, DAS28-ESR, DAS28-CRP, CRP, ESR, anti-CCP antibody status, rheumatoid factor status, and serum 25OHD (ng/ml). Diagnosis was recorded at 0 and 12 months onwards as either RA, Undifferentiated Inflammatory Arthritis (UIA; synovitis not meeting other classification/diagnostic criteria), Clinically Suspect Arthralgia (CSA; arthralgia of an inflammatory type without synovitis), or Other. Baseline demographic data were similar between all groups, with median symptom duration of 16.8-34.0 days. Baseline 25OHD was not significantly different between groups [median, interquartile range (IQR): RA 46.7, 30.0-73.3; UIA 51.4, 30.0-72.3; CSA 47.7, 30.3-73.0; Other 39.9, 28.6-62.2]. In RA ( There was no clear association between serum 25OHD and baseline diagnosis, RA disease activity, or progression from UIA or CSA to RA. Future studies of other vitamin D metabolites may better define the complex role of vitamin D in RA.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have linked rheumatoid arthritis (RA) risk and disease activity with vitamin D-deficiency (low serum 25-hydroxyvitamin D (25OHD)), but a causal role for vitamin D in RA is still unclear, with conflicting results from many previous studies, partly due to heterogeneity in study design and patient populations. In this study we aimed to (1) analyse serum 25OHD in early inflammatory arthritis, (2) compare 25OHD with disease activity and fatigue in early RA and (3) determine whether low 25OHD is associated with progression to RA.
METHODS
METHODS
An analysis of 790 patients recruited to the Birmingham Early Inflammatory Arthritis Cohort and followed longitudinally to determine clinical outcomes. The following were recorded at baseline: demographic data, duration of symptoms, duration of early morning stiffness (EMS), tender and swollen joint counts, Visual Analogue Scale (VAS) pain/fatigue/EMS, PHQ-9, HAQ and FACIT-Fatigue scores, DAS28-ESR, DAS28-CRP, CRP, ESR, anti-CCP antibody status, rheumatoid factor status, and serum 25OHD (ng/ml). Diagnosis was recorded at 0 and 12 months onwards as either RA, Undifferentiated Inflammatory Arthritis (UIA; synovitis not meeting other classification/diagnostic criteria), Clinically Suspect Arthralgia (CSA; arthralgia of an inflammatory type without synovitis), or Other.
RESULTS
RESULTS
Baseline demographic data were similar between all groups, with median symptom duration of 16.8-34.0 days. Baseline 25OHD was not significantly different between groups [median, interquartile range (IQR): RA 46.7, 30.0-73.3; UIA 51.4, 30.0-72.3; CSA 47.7, 30.3-73.0; Other 39.9, 28.6-62.2]. In RA (
CONCLUSIONS
CONCLUSIONS
There was no clear association between serum 25OHD and baseline diagnosis, RA disease activity, or progression from UIA or CSA to RA. Future studies of other vitamin D metabolites may better define the complex role of vitamin D in RA.
Identifiants
pubmed: 32728658
doi: 10.1186/s41927-020-00134-7
pii: 134
pmc: PMC7384217
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38Subventions
Organisme : Medical Research Council
ID : MR/P021220/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors have no competing interests to declare.
Références
Scand J Immunol. 2018 Sep;88(3):e12704
pubmed: 30048002
Arthritis Rheum. 2006 Nov;54(11):3719-20
pubmed: 17075887
Nat Rev Rheumatol. 2016 Apr;12(4):201-10
pubmed: 26481434
Arthritis Rheum. 2010 Jan;62(1):132-42
pubmed: 20039421
Arthritis Rheum. 2011 Jan;63(1):73-83
pubmed: 20954258
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14751-6
pubmed: 20679229
Arthritis Res Ther. 2014 Apr 17;16(2):R97
pubmed: 24742142
JAMA. 2018 Oct 2;320(13):1360-1372
pubmed: 30285183
Calcif Tissue Int. 2020 Jan;106(1):58-75
pubmed: 31286174
Calcif Tissue Int. 1998 Mar;62(3):193-8
pubmed: 9501950
Biomed Res Int. 2019 Mar 18;2019:8326246
pubmed: 31011579
J Steroid Biochem Mol Biol. 2019 Mar;187:1-8
pubmed: 30611909
Nutrients. 2015 Apr 22;7(4):3011-21
pubmed: 25912039
Curr Rheumatol Rev. 2017;13(3):170-179
pubmed: 28460627
J Autoimmun. 2018 Mar;88:50-60
pubmed: 29066221
PLoS One. 2015 Jul 02;10(7):e0131539
pubmed: 26134669
Clin Exp Immunol. 2017 Jan;187(1):113-123
pubmed: 27667787
Int J Rheum Dis. 2017 Jul;20(7):825-831
pubmed: 26481198
Front Immunol. 2019 Feb 07;10:178
pubmed: 30792721
J Rheumatol. 1998 Jun;25(6):1072-7
pubmed: 9632066
J Immunol. 2009 Nov 1;183(9):5458-67
pubmed: 19843932
J Rheumatol. 2019 Dec 15;:
pubmed: 31839594
RMD Open. 2017 Nov 14;3(2):e000479
pubmed: 29177078
Rheumatology (Oxford). 2015 Feb;54(2):374-5
pubmed: 25406355
Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1056-1060
pubmed: 30148432
Semin Arthritis Rheum. 2004 Dec;34(3):575-84
pubmed: 15609261
Arthritis Res Ther. 2010;12(6):R216
pubmed: 21114806
Cell Physiol Biochem. 2016;40(3-4):743-756
pubmed: 27915349
J Clin Endocrinol Metab. 1983 Dec;57(6):1308-10
pubmed: 6313738
Arthritis Rheum. 2004 Jan;50(1):72-7
pubmed: 14730601
PLoS One. 2016 Jan 11;11(1):e0146351
pubmed: 26751969
J Immunol. 2011 Jan 1;186(1):132-42
pubmed: 21131424
Immunology. 2016 Jul;148(3):227-36
pubmed: 27040466
Clin Exp Rheumatol. 2019 Jul-Aug;37(4):519-534
pubmed: 31140394
Am J Transl Res. 2018 Aug 15;10(8):2737-2746
pubmed: 30210711